Bradmer Pharmaceuticals, Inc. is dedicated to the development and commercialization of new and innovative cancer therapies.

We Identify, license, clinically test, and bring to market promising new anti-cancer drugs that have been discovered at leading academic and commercial research centers around the world.

The Company’s first product candidate, Neuradiab, invented by world-class scientists at Duke University, represents a significant advance in the treatment of certain brain cancers.